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Departments of Pathology, Universities of Leiden and Gronigen, The Netherlands
The relationship of experimentally produced renal lesions to
Bright's disease is still a major concern of present day pathol-
ogy even though the problem has for many years held the
attention and interest of numerous investigators.
Horn, 1937 [1]
Since Bright in 1827 [21 associated renal pathophysiology
with structural alterations in the kidney, many investigators
have been concerned with the study of kidney diseases, in
particular their natural history. Because biopsy techniques
were not available at that time, most cases of glomerulonephri-
tis could not be studied before they had reached an end stage.
In order to study the acute and early changes of glomerulone-
phritis and to understand their pathogenesis, experimental
models were developed in laboratory animals.
Logically the experiments performed in this era were char-
acterized by the prevailing thoughts on pathogenesis, and since
glomerulonephritis was often associated with bacterial infec-
tions, investigators tried to induce such a disease in animals
with bacterial toxins [3] or chemical compounds [1]. At the turn
of the century it was realized that glomerulonephritis was
caused by immunologic or rather allergic reactions against
bacterial products [4—6] and this precipitated a series of exper-
iments in which glomerulonephritis was induced by administra-
tion of bacteria or bacterial products [7—9], serum [10—13] or
purified serum proteins [14—171.
The first successful experimental model was reported by
Lindemann in 1900 [18], who succeeded to induce a prolifera-
tive glomerular lesion by injecting rats with an anti-kidney
antibody. Although a proliferative lesion was recognized in the
glomeruli, which appeared to be similar to that seen in human
post-infectious glomerulonephritis, the human counterpart of
this model was not discovered until 1967 [19].
A major breakthrough in experimental glomerulonephritis
came in 1953 when Germuth [20] introduced a form of glomer-
ulonephritis associated with experimental serum sickness. With
this model his group and that of Dixon [21] demonstrated that
glomerulonephritis was caused by deposition of immune com-
plexes which were formed in the circulation in a state of antigen
excess.
Another highlight in the history of experimental glomerulo-
nephritis has been the demonstration that glomerular immune
aggregates also can be formed in situ through a reaction of
antibody with fixed or planted glomerular antigens [22—24].
Moreover the elucidation of the glomerular filter as a charge
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and size selective barrier [25, 26] had important implications for
hypotheses on the pathogenesis of immunologically-induced
glomerular injury [27, 28].
And lastly progressive glomerulosclerosis spontaneously oc-
curring in certain rat strains has contributed to our understand-
ing of the progression of renal disease in man and its prevention
[29].
Although models of glomerulonephritis have advanced our
knowledge on glomerular disease in general, the relevance of
some aspects of experimental models has been questioned. The
histopathological expression of several forms of glomerulone-
phritis shows characteristics which prove difficult to attribute to
the immunological mechanisms thought to operate in experi-
mental disease [30], and furthermore, glomerular lesions unre-
lated to immunological mechanisms were shown to express a
similar variety of histopathological features. For the induction
of a glomerulonephritis, animals usually are immunized with
large, non-physiological doses of antigen. Moreover, injection
of glomerulonephritis inducing antibodies elicits an immune
reaction in the host to the injected foreign proteins which
complicates the disease and its pathogenesis.
Models of glomerulonephritis models induced by disturbed
regulation of the immune system associated with polyclonal
activation of B-lymphocytes (PBA) [31] are complicated, unlike
the naturally occurring diseases, by a down-regulation [32] and
therefore lack the chronic course which is characteristic for the
human situation. Glomerular lesions based on autoimmune
reactions of long duration can therefore be studied only in the
lesions occurring spontaneously in certain mice strains 133].
Notwithstanding these objections raised by the imperfection
of the glomerulonephritis models, we know that although none
of the existing models presents an identical copy of a form of
human glomerulonephritis, the total array of models provide a
reasonable complete picture of glomerulonephritis, each model
contributing essential details to this picture. Although it re-
mains hazardous to extrapolate the results from experimental
studies to human pathology, we have to acknowledge that
models of glomerulonephritis have given us (and still do so) an
insight in the pathogenesis of glomerulonephritis, Much less is
known about the etiologic factors underlying the induction of
glomerulonephritis. Promising in this respect are recent studies
concerning PBA as a common cause of different forms of
autoimmune glomerulonephritis, and also studies on genetical-
ly-determined vascular reactivity as a cause for progressive
glomerular sclerosis.
It is not the intention of this paper to present a comprehen-
sive overview of models of glomerulonephritis. Only some of
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Table 1. Models of glomerulonephritis
Immunologically induced Nephrotoxic serum nephritis
Heymann nephritis
Serum sickness nephritis
IgA glomerulonephritis
Models with polyclonal B cell
activation
Spontaneously occurring Models of SLE nephritis
Focal glomerulosclcrosis
the models will be discussed which in the past have contributed
to the understanding of human glomerulonephritis and to our
opinion still may do so. The models to be discussed are
presented in Table 1.
Nephrotoxic serum nephritis
Nephrotoxic nephritis, Masugi nephritis, and anti-GBM gb-
merulonephritis are all descriptions of one renal disease medi-
ated by heterologous antibody directed against antigens of the
glomerular basement membrane (GBM) [34, 35].
Upon injection, the antibody binds linearly along the GBM as
observed in immunofluorescence [36] and the animals develop a
proliferative glomerulonephritis with variable degrees of extra-
capillary proliferation and crescent formation [37], further
characterized by an influx of polymorph nuclear leucocytes and
mononuclear cells [38].
The lesions of the autologous phase during which the animal
produces antibodies against the injected protein, in principle do
not differ from those in the heterologous phase, although
proteinuria is a more constant feature. Eventually the disease
results in chronic glomerulonephritis and renal failure [39].
The nephritogenic antigen involved in the induction of neph-
rotoxic serum nephritis is a glucose containing polysaccharide
isolated from the GBM by digestion with trypsin [40], but the
true nature of the antigen has not been elucidated. In the human
counterpart of the model, antibodies to the Goodpasture anti-
gen are thought to react with the globular domain of type IV
collagen of bovine GBM [41]. The antigens were found to have
a molecular weight of 26 and 58 kD, respectively [42].
In the so-called accelerated model of nephrotoxic serum
nephritis published by Naish et al [43] rats are preimmunized
with IgG from the species used to prepare the anti-GEM
antibody. The ensuing proliferative glomerulonephritis is asso-
ciated with an influx of polymorphonuclear leucocytes and
mononuclear phagocytes [44], but also with an infiltration of T
cells consisting mainly of T helper cells. This infiltrate precedes
an influx of macrophages as described by Tipping, Neale and
Holdsworth [45]. The same group [46] demonstrated a macro-
phage inhibition activity of these lymphocytes, indicating their
active role in accelerated NTN. Moorthy and Abreo [47] found
that in rats receiving subnephritic doses of nephrotoxic serum
an increase of the proteinuria could be induced by transfer of
lymphocytes sensitized to the nephrotoxic IgG.
Cyclosporine was able to prevent both T cell accumulation
and the subsequent macrophage induced injury, thus suggesting
a role for cell-mediated immunity experimental anti-GBM gb-
merulonephritis [45].
Autologous models of anti-GBM glomerulonephritis are
known from the work of Steblay and Lepper [48]. They are
induced by immunizing animals with homologous or heterolo-
gous GEM. The resulting anti-GEM antibody binds to the GEM
in a linear fashion and induces a severe crescentic glomerulo-
nephritis [49] which is sometimes associated with pulmonary
hemorrhage resembling Goodpasture's syndrome in man [50].
The disease can be transferred to naive animals by antibodies
present in the circulation [Sb]. EAG can be induced in a variety
of species. Bolton, Tucker and Sturgill [52] were able to
demonstrate an important role for cellular immunity in experi-
mental allergic glomerulonephritis in chickens. They showed
that bursectomy which abrogated antibody formation com-
pletely did not influence the occurrence of the disease, and they
were able to transfer the disease to naive animals with lympho-
cytes [53].
Nephrotoxic glomerulonephritis and its variants have been
important for the understanding of the role of antibodies,
mediators and inflammatory cells in causing (functional) dam-
age to the glomerubus [54].
Heymaun nephritis
In 1951 Heymann and Lund [55] introduced a form of
autoimmune glomerulonephritis induced through immunization
of Sprague-Dawley rats with kidney cortex homogenate. This
regimen resulted in an immune complex glomerubonephritis
associated with the nephrotic syndrome. Later Edgington,
Glassock and Dixson [56] baptized this nephritis "Autologous
Immune Complex Glomerulonephritis" and demonstrated that
autologous antigens from the brush border of the proximal
tubules of the rat kidney were present in the glomerular immune
aggregates and were involved in the induction of this experi-
mental nephritis. Because of its morphological similarity to
human membranous glomerulopathy and because of the asso-
ciation with the nephrotic syndrome Heymann nephritis is
regarded the model of human membranous glomerulopathy.
Around 1970 a heterologous variant was introduced which was
induced by one injection of heterologous antiserum directed
against the mentioned tubular antigens [57, 58].
Both variants of Heymann nephritis belong to the most
studied gbomerulonephritis models, and especially in the pas-
sive Heymann nephritis important discoveries were made that
resulted in a better understanding of experimental nephrology
in general and immune complex glomerulopathy in particular
[59]. These studies have contributed enormously to the under-
standing of the formation and disappearance of immune aggre-
gates in the glomerular capillary wall [60], the mechanisms
leading to proteinuria [61, 62], and the role of immune regula-
tion considering the renal tubular antigens mentioned [31].
In this model it was demonstrated for the first time that the
immune aggregates present at the epithelial side of the gbomer-
ular filter were not deposited there from the circulation, but
instead were formed in situ [22]. This local formation of
glomerular immune complex aggregates was also shown to
occur in other models of glomerulonephritis like passive serum
sickness gbomerulopathy [63, 64], spontaneous glomerulone-
phritis in New Zealand white rabbits [65], and many others.
The antigen involved in the Heymann nephritis was purified
by Kerjaschki and Farquhar [66] and was shown to consist of a
glycoprotein with a molecular weight of 330 kD. Apart from its
presence in the tubular brush border, the antigen was shown to
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presence in the tubular brush border, the antigen was shown to
be present on the cell membrane of the glomerular epithelial
cells, especially in coated pits [671.
Soon thereafter a second breakthrough as to immune com-
plex formation in this model was made by the group of Andres
[68]. They demonstrated in vitro that following a reaction with
the antibody, the antigen on the epithelial cell membrane was
cross linked, clustered and subsequently shed, probably
through an association with intermediate filaments like micro-
tubules [69]. It was furthermore demonstrated in vitro that
chioropromazine could prevent such a clustering and subse-
quent shedding [70]. The authors hypothesized that similar
events may occur in vivo and that the formed aggregates are
shed in the space between epithelial cells and basement mem-
brane [68].
Several authors are convinced that more antigens than gp330
are involved in this immune complex glomerulopathy. They
claim that a glycoprotein with a molecular weight of around 100
kD might also be involved and which may be essential in
crosslinking the gp330 molecules [71] and subsequent shedding
of the complex [72—76]. Bagchus et al [72] suggested that gp9O
plays such a role in the pathogenesis of passive Heymann
nephritis. They showed that antisera from which the anti-gp9O
activity had been removed did not bind to rat glomeruli after
perfusion.
In addition Hogendoorn et al [771 found that antibodies
directed against extracellular matrix components like laminin
and collagen type IV are present in the sera used to induce
passive Heymann nephritis and could also play a role in the
formation of gp330 containing immune aggregates.
Sporadic reports in the literature on human nephropathology
deal with the presence of tubular brush border antigens (RTE)
in the glomerular aggregates of idiopathic membranous glomer-
ulopathy. Douglas et al [78] were able to detect circulating
anti-RTE antibodies in the serum of a patient with idiopathic
membranous glomerulopathy. They demonstrated RTE-like
antigens in the glomerular immune aggregates. These findings
suggest that RTE-like antigens might play a role in the patho-
genesis of some cases of human idiopathic membranous gb-
merulopathy. However, since the reports on the participation of
RTE antigens are limited despite an intensive search [79], and
because other antigens are known to be involved in secondary
membranous glomerulopathy [80], it seems likely that more
membrane or planted antigens are involved in the pathogenesis
of this disease.
In conclusion we can say that the study of Heymann nephri-
tis, and especially its passive variant, has helped us understand
the formation of glomerular immune aggregates. These result
from binding of antibodies to glomerular epithelial antigens that
subsequently are shed in the space between epithelial cell and
GBM. It provided an opportunity to study the role of comple-
ment and epithelial cell detachment as causes of increased
permeability of the glomerular filter. That in human glomerulo-
nephritis identical antigens are seldomly found doesn't neces-
sarily imply that the pathogenetic mechanism shown for this
kind of glomerulonephritis is not operating in human disease.
Studies along the line of those presented here for the Heymann
nephritis may reveal pathogenetic antigens in man.
Serum sickness glomerulopathy
Serum sickness glomerubopathy is the classical model of
immune complex disease. It was introduced by Germuth [20]
and Dixon et al [21] and brought a new scientific region to the
study of immune complex diseases in general and glomerulone-
phritis in particular. The model consists of an acute and a
chronic variant induced in rabbits by one or more injections of
bovine serum albumin (BSA) resulting in most cases in glomer-
ulonephritis.
The acute variant is induced by one bolus injection of BSA.
The resulting anti-BSA antibodies combine with the antigen in
the circulation to form immune complexes.
Chronic serum sickness glomerulonephritis is induced by
multiple injections with BSA that are given daily in a dosage
which is determined by the antibody titers in such a way that a
continuous antigen excess exists and that the immune com-
plexes which are formed therefore remain small and soluble. In
both models the glomerubonephritis is thought to result from
glomerular deposition of soluble immune complexes present in
the circulation. Depending on their size, the immune complexes
are deposited either in the glomerular capillary wall (GCW) or
in the mesangium [81].
It is known that physicochemical characteristics play an
important role in the deposition of immune complexes. These
characteristics determine the equilibrium between immune ag-
gregates and immune complexes on the one hand and between
immune complexes and their components on the other hand,
[(AgAb)n AgAb Ag+Ab] [81, 82]. When immune com-
plexes are formed with antibodies of low avidity the equilibrium
shifts to the right, thus fulfilling a prerequisite for an in situ
formation of immune complexes in tissues, as was shown for
the Heymann nephritis. This hypothesis is consistent with
results obtained by various investigators [83, 84], who showed
that in chronic serum sickness, membranous glomerulonephri-
tis developed only in animals producing low-affinity antibodies
[85, 86].
Whether immune aggregates are formed in situ or are depos-
ited from the circulation, the anionic charge of the GCW plays
a significant role, either by providing a charge barrier [871, or a
site for planted antigen, especially when the antigen possesses
a positive charge [88]. For this reason, antigens bearing a
positive net charge have become important in the induction of
experimental glomerulonephritis, and presumably also in the
genesis of human gbomerubonephritis.
In 1982, Hoyer, Krueger and Seiler [89] demonstrated that
alternating renal perfusion with heparin and the polycation
protamine sulfate resulted in complexes with a localization in
the GCW that roughly indicated the negatively charged sites.
The in situ formation of these spherical protamine-heparin
complexes was shown not to be related to the observed
proteinuria [89, 90]. Following these experiments Fleuren,
Grond and Hoedemaeker [91] demonstrated for the first time
that in situ formation of gbomerubar immune aggregates could
occur when antigens, not related to the gbomerulus, were first
planted in the GCW where they were able to react subsequently
with the injected antibody. With an alternating perfusion sys-
tem using BSA and anti-BSA antibodies, they demonstrated the
formation of immune aggregates in the GCW of isolated rat
kidneys. These investigations were extended by Border and
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coworkers [28, 92, 93] and many other investigators [94—96]
using a variety of charged antigens.
The net charge of immune complexes also influences deposi-
tion in the glomerulus. When cationized immune complexes are
injected into an animal, a GCW localization may be obtained
[85, 97, 98] through an interaction of the immune complexes and
the intrinsic negatively charged sites of the GCW. The charge of
the antigen can also influence the nature of the resulting
immune complexes. Koyama et al [99] showed that both size
and avidity were determined by the charge of the antigen.
Iskander and Jenette [100], Lew, Staines and Steward [83],
and Lew and Steward [84] showed that high-affinity immune
complexes were deposited exclusively in the mesangial area,
whereas low-affinity immune complexes were localized in the
GCW, suggesting that the immune complexes might easily
dissociate and reform in situ in the GCW [101—104].
It can be said that the value of the serum sickness model is
twofold. First it provided an insight in the formation and
subsequent deposition of immune complexes in tissues. In this
deposition the charge of the antigen or the net charge of the
immune complexes play an important role. Moreover it showed
that glomerular immune complexes also can be formed locally,
especially when charged antigens are involved. These antigens
first are planted in the GCW and subsequently react with
circulating antibody.
Lastly, extra antigen or antibody or positively charged mol-
ecules may under certain circumstances cause disappearance of
glomerular immune aggregates by competition of binding with
the glomerular negative charges.
IgA glomerulopathy
Glomerulonephritis which is associated with mesangial IgA
deposition includes Berger's disease, Henoch-Schönlein gb-
merulonephritis and the so-called hepatic glomerulonephritis,
This paper will only discuss the models associated with a
mesangial deposition or local formation of IgA-containing im-
mune complexes.
Although IgA glomerulopathy has been studied since its
discovery in 1968 by Berger and Hinglais [105], it is still not
clear how the mesangial deposits can elicit tissue damage,
evolve and which possible antigens may be involved. For this
reason several investigators tried to induce similar glomerular
lesions in animals.
The first model of IgA glomerulopathy was obtained in
BABL/c mice bearing a IgA myeloma (MOPC-315) which
produces antibodies with a specificity for albumin conjugated
DNP [106]. IgA immune complexes were found in the glomer-
ular mesangium in the majority of such animals in vivo and were
shown to induce glomerular disease. When compared to IgG
complexes formed under similar circumstances, IgA containing
immune complexes were shown to have a great propensity for
glomerular deposition [107]. Johnson et al [108] demonstrated
that IgA containing immune complexes like those of IgG are
able to elicit injury in pulmonary alveoli, by activation of
complement and generation of reactive oxygen species. In
models of IgA glomerulopathy it has been shown that the
immune aggregates are only nephritogenic when the antigen has
an independent ability of complement activation. If this is not
the case, in addition to the IgA containing complexes small
amounts of complement fixing IgG or 1gM antibody have to
bind [109].
Since in human IgA nephropathy infiltrating leucocytes can
seldomly be found, the mechanisms of tissue injury by IgA
immune complexes may be different.
Because it is believed that the mucosal immune system plays
an important role in idiopathic recurrent hematuria or Berger's
syndrome [105] and since deposition of IgA in the glomerular
mesangium is often associated with viral respiratory or gastro-
intestinal syndromes, attempts have been made to obtain a
model by oral immunization of animals.
Emancipator, Gallo and Lamm [1101 induced a IgA nephrop-
athy by oral immunization of mice with ovalbumin. The fea-
tures of the experimentally-induced renal lesion resembled that
seen in human IgA nephropathy, in the sense that mesangial
deposition of IgA was obtained. These experiments delineated
the importance of the mucosal IgA immune response in the
origin of this disease, especially when it is associated with a
blockade of the reticulo-endothelial system [111]. Other inves-
tigators, however, reported that mice immunized orally with
TNP-ovalbumin failed to induce a IgA nephropathy [112].
These studies further showed that the immune complexes
contained predominantly polymeric IgA, as determined by the
detection of the J-chain in the mesangial deposits [110]. The
affinity of immune complexes containing polymeric IgA for the
mesangium contrasts with the lack of such affinity of immune
complexes containing monomeric IgA [59]. It is possible that
monomeric IgA may contribute to the formation of mesangial
aggregates by in situ binding. This was demonstrated by Chen,
Wong and Rifai [113] who showed that binding of monomeric
IgA occurred following mesangial deposition of polymeric IgA
containing immune complexes.
In relation to the idea that polymeric IgA is transported to the
bile circulation, investigators tried to induce mesangial IgA
deposition either through ligating the bile ducts [114] or render-
ing livers cirrhotic [115] by carbon tetrachloride. Both regimens
resulted in increased IgA containing macromolecules in the
mesangium. Secretory component (SC) was also found in the
mesangium in these experiments, since it is never found in
mesangial deposits in clinical IgA disease, these experiments
should be regarded critically as to their relevance for human
disease [116]. In humans the SC-dependent biliary transport of
IgA probably plays a much smaller role in the removal of
polymeric IgA from the plasma than in rats [117].
Thus far, the study of the models of IgA nephropathy has
shown that mesangial IgA deposits can follow oral immuniza-
tion of mice, but that this model does not mimic all features of
the human disease; in particular the functional gbomerular
disorders seem to be missing. Mesangial IgA containing im-
mune complexes, especially in aged mice, can be induced by
the ubiquitous occurring ocorna virus antigens [118]. This
means that the mouse is not an ideal animal for developing a
model for human IgA gbomerubopathy [119].
Models of glomerulonephritis associated with polyclonal B
cell activation
Common characteristics of the models described above is
that they occur spontaneously or are induced by immunization
with a well defined antigen. This antigen is either a normal
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constituent of the glomerular structures or becomes part of it by
deposition from the circulation. Upon binding, humoral and/or
cellular reactants cause a characteristic pattern of inflammatory
injury. Under normal conditions tolerance to self-antigens of
the glomerulus prevents the induction of autoimmune reactions
leading to glomerulonephritis. Immunization in complete
Freund's adjuvant is one of the mechanisms to by-pass or break
this tolerance. Under normal conditions tolerance is maintained
by an active system of suppression by specific T cells and
anti-idiotypic antibodies which control the expression of nor-
mally existing autoreactive T and B cells. Defaulting the sup-
pressor mechanisms will lead to uncontrolled expression of
autoreactive B cells resulting in the production of auto-anti-
bodies or autoreactive cytotoxic T-cells to various self-constit-
uents. Similarly, autoreactivity may be induced when B cell
activation is too strong to be controlled, for example by cross
linking of surface immunoglobulins, by stimulatory agents such
as LPS [120] or other viral or bacterial antigens [121], by
alloreactive lymphocytes in graft versus host (GVH) [1221 or
host versus graft (HVG) reactions [123] and by toxic agents
such as mercury [1241, and penicillamine [125].
Irrespective of the underlying cause, polyclonal B cell acti-
vation results in a characteristic autoimmune syndrome with
hypergammaglobulinemia including IgE, antinuclear antibod-
ies, anti-red blood cell (RBC) antibodies and anti-basement
membrane antibodies (especially of IgG1 and IgG2 isotypes),
vasculitis, glomerulonephritis and mucosal inflammation. The
susceptibility to PBA and glomerulonephritis upon the appro-
priate stimuli is genetically determined as shown in experiments
with LPS [126], mercury [127], the alloreactive stimulation by
GVH [128] or HVG [129]. In rodents LPS has been shown to
induce anti-DNA antibodies [130], anti-idiotype antibodies and
rheumatoid factor [131]. Glomerulonephritis has been found to
be associated with circulating immune complexes containing
antibodies of various specificities, and these could be eluted
from the diseased glomeruli. PBA and glomerulonephritis have
been described in models of malaria [132], and of Trypanoso-
miasis [133—135], and are characterized by genetically restricted
anti-DNA, rheumatoid factor and anti-basement membrane
autoantibody activity.
Examples of PBA associated with glomerulopathy will be
presented in the next paragraphs. The first two examples deal
with induced forms like allogeneic disease caused by GVH or
HVG and mercuric chloride-induced glomerulopathy. Models
of SLE will also be discussed as an example of spontaneously
occurring PBA associated with glomerulopathy.
Al/ogeneic disease
The autoimmune phenomena induced by chronic allogeneic
disease can be found in murine experimental GVH disease and
in HVG reactions in chimeras. GVH disease can be induced by
transfer of parental lymphocytes to an Fl hybrid derived from
a cross with another parent strain differing at the MHC class II
region. Genetic studies have revealed that such intra-class II
differences determine the susceptibility to stimulatory reactions
resulting in polyclonal B cell activation and auto-immune gb-
merulonephritis [121, 128, 136]. Autoantibodies develop which
are directed against RBC, basement membrane antigens [1371
and a renal tubular antigen with a molecular weight of 160 kD,
the pathogenicity of which is still uncertain [138]. All these
specificities can also be found in normal unstimulated mice, and
in increased amount upon exposure to certain stimuli, but
usually they are of the 1gM subclass, whereas in GVH they are
of IgG isotype [138]. The isotype switch which is under control
of IL-4 is probably of major importance in conditions associated
with T cell dependent PBA [139], as was also suggested for
HVG [140] and for mercury-induced autoimmune reactions
[141].
The HVG model of autoimmune disease is induced by
transfer of Fl lymphocytes into neonatal mice of one of the
parental strains. These mice develop tolerance to the graft but
stimulate the grafted B cells semi-allogeneically because of the
different MHC antigens on their T helper cells [142]. The
grafted B cells are not under normal control and this non-
cognate T-B cell cooperation, similar as that in GVH disease
results in autoantibody production and glomerulonephritis [122,
140].
Mercuric chloride-induced glomerulopathy
PBA associated With different forms of gbomerulonephritis
[143—145] has been well established in rodents exposed to
mercuric chloride. Depending upon the MHC and non-MHC
genes [1271, rats will develop either a stimulatory syndrome
characterized by PBA and glomerulonephritis, or suppression
phenomena as have been described in the Lewis rat [1461. The
model has been most extensively studied in the Brown-Norway
rat, which develops a T cell-dependent transient syndrome of
high IgE levels and IgG1 and IgG2 auto-antibodies directed
against components of the glomerular basement membrane
resulting in a linear and later granular distribution [1411 of
immune aggregates in the GCW [123, 132, 133, 141, 143]. The
early phase is associated with an increase in B and T lympho-
cytes, increased class II expression on lymphoid organs, epi-
thelia of salivary glands and the tongue [141]. The recovery
phase is associated with the presence of anti-idiotype antibodies
[147] and suppressor T cell activity [148] that can transfer
suppression to naive recipients. In vitro and in vivo studies
have demonstrated that early in the disease autoreactive T cells
develop. These are directed against class II antigens as well as
to other undefined T cell surface antigens and are likely to play
an important role in the disease [149]. In addition, mercury has
been shown to induce thymic depletion [141] and to affect
suppressor T cell function [150], which may also play a permis-
sive role in the induction of the disease.
SLE models
Murine models of lupus are often examples of PBA and
glomerulonephritis which have been studied extensively, for
example in murine lupus models in the (NZB x NZW)F 1 (B/W)
female mice, B x SD male and MRL-lpr/lpr mice [151, 152].
Following the report of Koffler, Schur and Kunkel [153] that
in human SLE glomerulonephritis the glomerular aggregates
were composed of DNA and anti-DNA, similar findings were
reported for the B/W mice [154] and later in the other mouse
strains [155—157]. After Izui, Lambert and Miescher [158] had
demonstrated an affinity of DNA for the collagen moiety of the
GBM in vitro, it was believed that apart from being deposited
from the circulation, glomerular immune aggregates in SLE
glomerulonephritis could also be formed in situ.
In 1984 O'Regan and Turgeon [159] found that infusion of
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DNA into normal mice resulted in mesangial binding and not in
a binding to the GCW which did not support such in situ
formation. Subsequent experiments similarly failed to demon-
strate in situ formation of glomerular immune aggregates in
experimental SLE [160], and rabbits infused with preformed
DNA anti-DNA immune complexes get mesangial deposits, but
not localization along the glomerular capillary wall [1611. These
findings questioned the importance of DNA-anti-DNA immune
complexes in the pathogenesis of SLE glomerulonephritis.
Although Morimoto et al [162] reported that in SLE patients the
disease activity was directly correlated with circulating immune
complexes consisting of DNA-anti-DNA, Izui, Lambert and
Miescher [163] showed that only 6% of the circulating immune
complexes in SLE patients consisted of DNA/anti-DNA and
that at least 52% of the immune complexes were of different
composition.
Comparable findings have been reported for the spontane-
ously occurring SLE-like syndromes in mice. Cavallo, Grave,
and Granholm [164] showed that the DNA anti-DNA content
was low in eluates from glomeruli of B/W mice and Izui et al
[165] showed that the presence of serum antibodies to single- or
double-stranded DNA was not significantly associated with the
occurrence of glomerulonephritis. Granholm et al [166] demon-
strated that the glomerular eluates from B/W mice contained a
factor that inhibited the interaction between DNA and anti-
DNA. All of these studies led to the conclusion that other
immune complex systems besides DNA anti-DNA could play a
role in the pathogenesis of lupus nephritis.
In 1981 Izui et al [165] found a correlation between the
development of fatal glomerulonephritis in B/W mice, and the
presence of gp70-containing immune complexes [167]. Gp70 is a
serum glycoprotein structurally related to the envelope glyco-
protein of murine leukemia virus [168]. Although this virus has
a virtually ubiquitous occurrence in rodents, only lupus-prone
animals develop auto-antibodies against gp7O spontaneously
[169]. Izui et al [165] concluded from these findings that
gp7O-anti-gp7O systems fulfill a pathogenic role in experimental
lupus nephritis and that genes governing the production of
auto-antibodies against retroviral gp7O may be the genes mainly
responsible for the segregation of spontaneous renal disease in
B/W mice.
However Andrews et al [170] have recently questioned the
role of the anti-gp7O immune response in murine SLE. They
used a low gp7O MRL/1 cogenic mice to demonstrate that
elimination of most of the serum gp7O and virtually all of the
immune complexes containing gp7O had no observable effect on
the course or nature of the disease.
So far it can be concluded that the spontaneously occurring
SLE-like disease associated with glomerulonephritis in certain
mouse strains has served as a model of human SLE glomeru-
lonephritis. Their study has provided several competing
hypotheses of pathogenetesis [171], and further studies will be
needed before it can be ascertained which of these are pertinant
to clinical SLE.
Focal and segmental glomeruloscierosis
Mechanisms involved in the progression of renal disease have
been studied in experimental models from the beginning of this
century. But during the last decade renewed interest and the
use of micropuncture and morphometry combined with phar-
macological and dietary intervention have provided enormous
gain in the understanding of the factors determining the pro-
gression of renal disease.
Progressive glomerulosclerosis develops in certain rat strains
spontaneously with aging [172, 173] and bears a close resem-
blance to focal glomerulosclerosis in man, an entity first de-
scribed by Habib et al [174]. Later it was recognized as a form
of glomerular injury that can complicate various forms of renal
disease as well as systemic disease, such as hypertension and
diabetes mellitus [29]. The development of experimental pro-
gressive glomerulosclerosis can be accelerated by high protein
feeding [175], by renal ablation [1761, and by inducing systemic
hypertension [177] or diabetes mellitus [178]. In addition,
progressive glomerulosclerosis can develop in genetic models
of hypertension with or without unilateral nephrectomy and in
models of obesity [179]. Finally, progressive glomeruloselerosis
has been described in models of chronic glomerular epithelial
cell damage induced by puromycin aminonucleoside [180] and
adriamycin [181]. It has been suggested that hemodynamic
factors, and most importantly intraglomerular capillary pres-
sures, play a crucial role in the pathogenesis of progressive
glomerulosclerosis [182, 183], via endothelial, mesangial and
epithelial damage and glomerular hypertrophy [184]. Endothe-
hal cell damage is associated with platelet aggregation and
thrombosis, which may explain the beneficial effect of anti-
coagulatory treatment [185, 186]. The susceptibility to develop
progressive glomerulosclerosis is genetically determined [29,
187] and probably depends upon the vasoactive responses to a
primary glomerular injury, such as in diabetes mellitus or in
minimal change disease in man, and similarly after unilateral
nephrectomy or high protein feeding in experimental models
[29]. Intervention aimed at lowering capillary pressure either by
protein restriction (afferent constriction) or converting enzyme
inhibition (efferent vasodilation) have been shown to be par-
tially effective in preventing or retarding progressive glomeru-
losclerosis in experimental models [175. 181, 183, 188—190]; it
should be remembered that these treatments have other effects
beside those on glomerular capillaries. Similar results have
been claimed in clinical studies but more data are needed [191—
193].
The models of progressive glomeruloscierosis have provided
insight in functional abnormalities that eventually lead to end-
stage renal failure, especially when the lesions closely resemble
those of human focal glomerulosclerosis. In other models, such
as experimental diabetes in rats, the lesions do not show the
typical morphological picture found in man, and here extrapo-
lation seems hazardous. In addition it should be remembered
that most male rats are prone to develop progressive glomeru-
losclerosis with age and that man seems to be less susceptible.
Genetic differences in susceptibility associated with vascular
reactivity seem to be crucial in identifying individuals at risk.
Conclusion
In the eighty years during which experimental models of
human glomerulonephritis have been studied, much has been
learned about the mechanisms by which glomerular immune
aggregates are formed, how they mediate glomerular injury,
leading to an increased permeability and how progression to
end-stage renal failure occurs. In recent years the emphasis of
the studies has shifted towards the role of cellular immunity and
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mediators of inflammation. Taken together, however, the stud-
ies mentioned above have not resulted yet in a complete picture
of human glomerulopathy in all its variants and its pathophys-
iological consequences. This is due to the fact, although be-
lieved otherwise, that it is seldom possible to obtain a disease
model in which both etiology and pathogenesis are identical or
even similar to human disease. The study of models often is
complicated by the fact that they are induced by methods which
do not occur naturally or are complicated by the induction of an
immune reaction in animals which is directed against the
disease-inducing antibody. Furthermore in models of glomeru-
lonephritis resulting from autoimmunity, the induced autoim-
mune phenomena are downregulated so that the disease re-
solves spontaneously and chronic disease cannot be studied in
detail.
These drawbacks however do not invalidate the observations
made already. The study of a model frequently involves the
elucidation of a detail, like participation of a mediator of
inflammation or the mechanism causing increased permeability
of the glomerulus. The results from such studies may lead to the
formulation of a working hypothesis which can be used for the
study of human glomerulonephritis or for development of
additional models for study. Ultimately the results from such
studies have proved their relevance to human nephropathology,
and can lead to clinical advances such as the development of
treatment modalities or even preventative measures. Until now
though, this has hardly happened.
The reason why results from studies of experimental glomer-
ulonephritis are not used more often, may be due to the fact that
most models were developed for the studies of pathogenetic
mechanisms, which in the human situation hardly appear to be
accessible for treatment. Nevertheless, the study of spontane-
ously-occurring autoimmune phenomena in mice and more
recently of induced autoimmune phenomena by PBA have
opened new and exciting possibilities for the study of etiologic
factors in human glomerulopathy. Although postinfectious gb-
merulonephritis has almost disappeared, additional extrinsic
factors like bacteria, viruses or drugs may prove to be impor-
tant in eliciting an PBA in susceptible individuals. The recog-
nition of such a mechanism then may lead to the prevention of
some forms of glomerulonephritis.
Reprint requests to Professor P.J. Hoedemaeker, Department of
Pathology, University of Leiden, P.O. Box 9603, 2300 RC Leiden, The
Netherlands
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